NIAID DCR OPERATIONAL TASK ORDERCOVID FUNDING SUPPORTS THE NIAID DCR COVID WEBSITE AND THE VARIANT TESTING SAVE PROGRAM FOR VARIANT TESTING.

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: BARRY  GAUSE
Organization: LEIDOS BIOMEDICAL RESEARCH, INC.
Fiscal Year: 2022
Award: $1,200,000
Funding agency: National Institute of Allergy and Infectious Diseases

COVID SARS-CoV-2 Assessment Viral Evolution (SAVE) variant testing provides support for analysis of SARS-CoV-2 genome sequences from specimens collected in COVID-19 therapeutic and observational trials for genetic variants that could impact diagnostics, therapeutics, vaccine efficacy, and disease severity. Additional genome sequencing will be done at NIAID Special Projects on samples collected from observational studies and for diagnostic purposes. This will broaden the understanding of the circulation of SARS-CoV-2 variants. COVID SAVE provides support for the analysis of the impact of SARS-CoV-2 variants in vitro neutralization assays. Additionally, COVID SAVE variant testing allows analysis of the evolution of SARS-CoV-2 and identification of future variants with potential public health impacts

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Allergy><Assay><Bioassay><Biologic Assays><Biological Assay><Blood Circulation><Bloodstream><COVID><COVID-19 affected><COVID-19 consequence><COVID-19 effect><COVID-19 genome><COVID-19 impact><COVID-19 impacted><COVID-19 testing><COVID-19 therapeutics><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus genome><COVID19 genome><COVID19 testing><COVID19 therapeutics><COVID19 virus><COVID19 virus genome><Circulation><Clinical Research><Clinical Study><Clinical Treatment Moab><CoV disease><CoV-2><CoV2><Contracting Opportunities><Contracts><Diagnostic><Epidemiology><Evolution><Funding><Future><Gene variant><Genome><Hypersensitivity><Immune Evasion><Immune response><Immunological response><In Vitro><Infection><Institutes><Investigators><Location><Monoclonal Antibodies><NIAID><National Institute of Allergy and Infectious Disease><Observation research><Observation study><Observational Study><Observational research><Public Health><Research Personnel><Research Specimen><Researchers><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 genome><SARS-CoV-2 testing><SARS-CoV-2 therapeutics><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 genome><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Specimen><Testing><Therapeutic><Variant><Variation><Viral><Virus><Wuhan coronavirus><allele variant><allelic variant><corona virus disease><coronavirus disease><coronavirus disease 2019 consequence><coronavirus disease 2019 effect><coronavirus disease 2019 genome><coronavirus disease 2019 impact><coronavirus disease 2019 testing><coronavirus disease 2019 therapeutics><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease 2019 virus genome><coronavirus disease-19 impact><coronavirus disease-19 virus><disease severity><entire genome><epidemiologic><epidemiological><full genome><genetic variant><genome sequencing><genomic variant><hCoV19><host response><immune system response><immunoresponse><mAbs><nCoV2><severe acute respiratory syndrome coronavirus 2 genome><severe acute respiratory syndrome coronavirus 2 testing><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><vaccine efficacy><web site><website><whole genome>